NCT04499053 - Durvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 9, 2020

Primary Completion Date

February 28, 2027

Study Completion Date

December 31, 2027

Conditions

Carcinoma, Non-Small Cell Lung

Interventions

DRUG

Durvalumab

durvalumab 1500 mg, intravenous, every 3 weeks for 4 cycles, followed by 1500 mg, intravenous, every 4 weeks (maintenance treatment)

DRUG

Tremelimumab

tremelimumab 75 mg, intravenous, every 3 weeks for 4 cycles. A dose of tremelimumab 75 mg will be given at week 16.

Trial Locations (4)

RECRUITING

Georgetown Lombardi Comprehensive Cancer Center, Washington D.C.

RECRUITING

Medstar Washington Hospital Center, Washington D.C.

RECRUITING

Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore

RECRUITING

Harry and Jeannette Weinberg Cancer Institute at Franklin Square, Baltimore